サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1460612

疫学における人工知能（AI）の世界市場予測（2024年～2032年）

Global Artificial Intelligence (AI) in Epidemiology Market Forecast 2024-2032
出版日: | 発行: Inkwood Research | ページ情報: 英文 299 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
疫学における人工知能（AI）の世界市場予測（2024年～2032年）
出版日: 2024年04月02日
発行: Inkwood Research
ページ情報: 英文 299 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主な調査結果

世界の疫学における人工知能（AI）の市場規模は、2024年～2032年の予測期間でCAGR27.33％を生み出すと予測されています。主な市場の成長促進要因としては、疾病発生の早期発見と監視、疾病動向予測のための予測モデリングのニーズの高まり、疫学調査用のデータ利用可能性などが挙げられます。

市場の洞察

疫学における人工知能（AI）の世界市場の成長を促進する上で、疾病発生の早期発見と監視が極めて重要な役割を果たしています。膨大なデータセットにAIを搭載したアルゴリズムを活用することで、公衆衛生当局は新たな脅威を迅速に特定することができ、感染症の蔓延を緩和するためのタイムリーな介入が可能になります。このプロアクティブなアプローチは、人命を救うだけでなく、広範なアウトブレイクの治療に関連するヘルスケアコストを削減します。

さらに、疫学におけるAIの導入は、疾病監視システムの効率と精度を高め、集団の健康動向をリアルタイムで監視することを可能にします。この機能により、ヘルスケアのステークホルダーは、潜在的なアウトブレイクを予測し、リソースを効果的に配分し、的を絞った介入を実施することが可能となり、公衆衛生と経済に対する伝染病の影響を最小限に抑えることができます。

疫学調査と公衆衛生インフラへのAI技術の統合が進むにつれて、政府、研究機関、業界関係者の連携が促進されます。こうしたパートナーシップは、AIアルゴリズムとデータ分析におけるイノベーションを促進し、疾病の検出、予測、対応のためのより洗練されたツールの開発につながります。その結果、疫学におけるAIソリューションの需要は急増を続け、利害関係者が公衆衛生を守る上で早期発見とサーベイランスの重要な役割を認識するにつれて、世界市場の成長を促進しています。

地域別洞察

世界の疫学における人工知能（AI）の市場成長調査は、欧州、アジア太平洋、北米、その他の地域の地理的調査をまとめています。北米は予測期間中、世界市場の主要地域となる見込みです。

北米は、電子カルテ（EHR）や強力なデータシステムなどの高度なツールを備えた洗練されたヘルスケアインフラを誇り、AIソリューションのシームレスな統合と利用を可能にしています。政府説明責任局（GAO）と全米医学アカデミー（NAM）は、ヘルスケアにおけるAI/ML用途を調査し、その影響を評価し、その利用を最適化するための主要戦略を特定するイニシアティブで協力しています。この取り組みは、北米の疫学におけるAI市場の進展を大きく加速させています。

競合考察

疫学におけるAIの競合情勢では、各社が高度なアルゴリズムとデータ分析を活用して革新的なソリューションを提供し、疾病の監視と予測を強化しようと競い合っています。主な企業は、膨大なヘルスケアデータを効率的に分析し、公衆衛生機関や医療提供者に実用的な洞察を提供できる堅牢なAIモデルの開発に注力しています。

さらに、研究機関や政府機関との提携は、急速に進化するこの市場で優位に立つために極めて重要です。さらに、世界市場の上位企業には、Epic Systems Corporation, Microsoft Corporation, Meditech,などがあります。

目次

第1章 調査範囲と調査手法

第2章 エグゼクティブサマリー

  • 市場規模・推計
  • 市場概要
  • 調査範囲
  • 危機シナリオ分析
  • 主な市場調査結果

第3章 市場力学

  • 主な促進要因
    • 疾病発生の早期発見と監視
    • 疾病動向予測のための予測モデリング
    • 疫学調査のためのデータ利用可能性
  • 主な抑制要因
    • 機密性の高い患者データに関するプライバシーと倫理的懸念
    • データの質と可用性に関する課題

第4章 主要分析

  • 主要市場動向
    • 機械学習とデータ分析の進歩
    • 遠隔医療と遠隔モニタリングの拡大
    • 公衆衛生システムにおけるAIの統合
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 市場成熟度分析
  • 市場集中度分析

第5章 市場：展開別

  • オンプレミス
    • 市場予測図
    • セグメント分析
  • ウェブベース
    • 市場予測図
    • セグメント分析
  • クラウドベース
    • 市場予測図
    • セグメント分析

第6章 市場：用途別

  • 感染予測
    • 市場予測図
    • セグメント分析
  • 疾病・症候群サーベイランス
    • 市場予測図
    • セグメント分析
  • 集団健康と罹患率/有病率のモニタリング
    • 市場予測図
    • セグメント分析

第7章 市場：最終用途別

  • 政府・州機関
    • 市場予測図
    • セグメント分析
  • 研究所
    • 市場予測図
    • セグメント分析
  • 製薬・バイオテクノロジー企業
    • 市場予測図
    • セグメント分析
  • 医療提供者
    • 市場予測図
    • セグメント分析

第8章 地域分析

  • 北米
    • 市場規模・推計
    • 市場促進要因
    • 市場の課題
    • 市場の主要企業
    • 国別分析
  • 欧州
    • 市場規模・推計
    • 市場促進要因
    • 市場の課題
    • 市場の主要企業
    • 国別分析
  • アジア太平洋
    • 市場規模・推計
    • 市場促進要因
    • 市場の課題
    • 市場の主要企業
    • 国別分析
  • 世界のその他の地域
    • 市場規模・推計
    • 市場促進要因
    • 市場の課題
    • 市場の主要企業
    • 地域別分析

第9章 競合情勢

  • 主な戦略的発展
    • 合併・買収
    • 製品発売・開発
    • 提携・協定
    • 事業拡大・縮小
  • 企業プロファイル
    • ALPHABET INC
    • BAYER HEALTHCARE
    • CARDIOLYSE
    • CERNER CORPORATION
    • COGNIZANT
    • ECLINICAL WORKS INC
    • EPIC SYSTEMS CORPORATION
    • INTEL CORPORATION
    • KOMODO HEALTH
    • MEDITECH
    • MICROSOFT CORPORATION
    • PREDIXION HEALTHCARE（JVION LLC）
    • SAS INSTITUTE
    • SIEMENS HEALTHINEERS
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY
  • TABLE 2: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 4: GLOBAL ON-PREMISE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: GLOBAL ON-PREMISE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 6: GLOBAL WEB-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: GLOBAL WEB-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 8: GLOBAL CLOUD-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: GLOBAL CLOUD-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 12: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 13: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 14: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 15: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 16: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 17: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 19: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 20: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 21: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 22: GLOBAL RESEARCH LABS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 23: GLOBAL RESEARCH LABS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 24: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 26: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 27: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 28: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 29: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 30: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 31: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 32: KEY PLAYERS OPERATING IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 33: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 34: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 35: KEY PLAYERS OPERATING IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 36: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 37: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 38: KEY PLAYERS OPERATING IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 39: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 40: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 41: KEY PLAYERS OPERATING IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 42: LIST OF MERGERS & ACQUISITIONS
  • TABLE 43: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 44: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 45: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING
  • FIGURE 4: MARKET MATURITY ANALYSIS
  • FIGURE 5: MARKET CONCENTRATION ANALYSIS
  • FIGURE 6: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY DEPLOYMENT, IN 2023
  • FIGURE 7: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY ON-PREMISE, 2024-2032 (IN $ MILLION)
  • FIGURE 8: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY WEB-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 9: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY CLOUD-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
  • FIGURE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY INFECTION PREDICTION & FORECASTING, 2024-2032 (IN $ MILLION)
  • FIGURE 12: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DISEASE & SYNDROMIC SURVEILLANCE, 2024-2032 (IN $ MILLION)
  • FIGURE 13: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE, 2024-2032 (IN $ MILLION)
  • FIGURE 14: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY END USE, IN 2023
  • FIGURE 15: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GOVERNMENT & STATE AGENCIES, 2024-2032 (IN $ MILLION)
  • FIGURE 16: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY RESEARCH LABS, 2024-2032 (IN $ MILLION)
  • FIGURE 17: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2024-2032 (IN $ MILLION)
  • FIGURE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY HEALTHCARE PROVIDERS, 2024-2032 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 20: UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 21: CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 22: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 23: UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 24: GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 25: FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 26: ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 27: SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 29: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 30: CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 31: JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 32: INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 34: AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 35: REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 36: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 37: LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
目次
Product Code: 82541

KEY FINDINGS

The global artificial intelligence (AI) in epidemiology market is forecasted to generate a CAGR of 27.33% over the projection years of 2024-2032. Key drivers facilitating the market's growth include the early detection and surveillance of disease outbreaks, the growing need for predictive modeling to forecast disease trends, and data availability for epidemiological research.

MARKET INSIGHTS

Early detection and surveillance of disease outbreaks play a pivotal role in driving the growth of the global artificial intelligence (AI) in epidemiology market. By leveraging AI-powered algorithms on vast datasets, public health authorities can swiftly identify emerging threats, enabling timely interventions to mitigate the spread of infectious diseases. This proactive approach not only saves lives but also reduces healthcare costs associated with treating widespread outbreaks.

Furthermore, the adoption of AI in epidemiology enhances the efficiency and accuracy of disease surveillance systems, enabling real-time monitoring of population health trends. This capability enables healthcare stakeholders to anticipate potential outbreaks, allocate resources effectively, and implement targeted interventions, thereby minimizing the impact of epidemics on public health and economies.

The increasing integration of AI technologies into epidemiological research and public health infrastructure fosters collaborations between governments, research institutions, and industry players. These partnerships drive innovation in AI algorithms and data analytics, leading to the development of more sophisticated tools for disease detection, prediction, and response. Consequently, the demand for AI solutions in epidemiology continues to surge, fueling the growth of the global market as stakeholders recognize the critical role of early detection and surveillance in safeguarding public health.

REGIONAL INSIGHTS

The global artificial intelligence (AI) in epidemiology market growth examination compiles the geographical study of Europe, Asia-Pacific, North America, and Rest of World. North America is set to be a major region in the global market during the forecast period.

North America boasts a sophisticated healthcare infrastructure with advanced tools like electronic health records (EHRs) and strong data systems, enabling seamless integration and use of AI solutions. The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) are collaborating on an initiative to explore AI/ML applications in healthcare, assessing their impact and identifying key strategies for optimizing their use. This effort significantly accelerates progress in the North America AI in epidemiology market.

COMPETITIVE INSIGHTS

In the competitive landscape of AI in epidemiology, companies are vying to offer innovative solutions leveraging advanced algorithms and data analytics to enhance disease surveillance and prediction. Key players are focused on developing robust AI models that can efficiently analyze vast amounts of healthcare data to provide actionable insights for public health agencies and healthcare providers.

Additionally, partnerships with research institutions and government bodies are crucial for staying ahead in this rapidly evolving market. Additionally, some of the top companies in the global market are Epic Systems Corporation, Microsoft Corporation, Meditech, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
    • 2.4.1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
    • 2.5.2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
    • 2.5.3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
    • 3.1.2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
    • 3.1.3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
  • 3.2. KEY RESTRAINTS
    • 3.2.1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
    • 3.2.2. DATA QUALITY AND AVAILABILITY CHALLENGES

4. KEY ANALYTICS

  • 4.1. KEY MARKET TRENDS
    • 4.1.1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
    • 4.1.2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
    • 4.1.3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
  • 4.2. PORTER'S FIVE FORCES ANALYSIS
    • 4.2.1. BUYERS POWER
    • 4.2.2. SUPPLIERS POWER
    • 4.2.3. SUBSTITUTES
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. GROWTH PROSPECT MAPPING
  • 4.4. MARKET MATURITY ANALYSIS
  • 4.5. MARKET CONCENTRATION ANALYSIS

5. MARKET BY DEPLOYMENT

  • 5.1. ON-PREMISE
    • 5.1.1. MARKET FORECAST FIGURE
    • 5.1.2. SEGMENT ANALYSIS
  • 5.2. WEB-BASED
    • 5.2.1. MARKET FORECAST FIGURE
    • 5.2.2. SEGMENT ANALYSIS
  • 5.3. CLOUD-BASED
    • 5.3.1. MARKET FORECAST FIGURE
    • 5.3.2. SEGMENT ANALYSIS

6. MARKET BY APPLICATION

  • 6.1. INFECTION PREDICTION & FORECASTING
    • 6.1.1. MARKET FORECAST FIGURE
    • 6.1.2. SEGMENT ANALYSIS
  • 6.2. DISEASE & SYNDROMIC SURVEILLANCE
    • 6.2.1. MARKET FORECAST FIGURE
    • 6.2.2. SEGMENT ANALYSIS
  • 6.3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
    • 6.3.1. MARKET FORECAST FIGURE
    • 6.3.2. SEGMENT ANALYSIS

7. MARKET BY END USE

  • 7.1. GOVERNMENT & STATE AGENCIES
    • 7.1.1. MARKET FORECAST FIGURE
    • 7.1.2. SEGMENT ANALYSIS
  • 7.2. RESEARCH LABS
    • 7.2.1. MARKET FORECAST FIGURE
    • 7.2.2. SEGMENT ANALYSIS
  • 7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 7.3.1. MARKET FORECAST FIGURE
    • 7.3.2. SEGMENT ANALYSIS
  • 7.4. HEALTHCARE PROVIDERS
    • 7.4.1. MARKET FORECAST FIGURE
    • 7.4.2. SEGMENT ANALYSIS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.1.3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.1.4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.1.1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.1.5.2. CANADA
      • 8.1.5.2.1. CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.2.3. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.2.4. KEY PLAYERS IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. UNITED KINGDOM
      • 8.2.5.1.1. UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.2. GERMANY
      • 8.2.5.2.1. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.3. FRANCE
      • 8.2.5.3.1. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.4. ITALY
      • 8.2.5.4.1. ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.5. SPAIN
      • 8.2.5.5.1. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.6. REST OF EUROPE
      • 8.2.5.6.1. REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.3.3. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.3.4. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.1.1. CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.2. JAPAN
      • 8.3.5.2.1. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.3. INDIA
      • 8.3.5.3.1. INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.4. SOUTH KOREA
      • 8.3.5.4.1. SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.5. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5.1. AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.6. REST OF ASIA-PACIFIC
      • 8.3.5.6.1. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.4.3. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.4.4. KEY PLAYERS IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.1.1. LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.4.5.2. MIDDLE EAST & AFRICA
      • 8.4.5.2.1. MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. ALPHABET INC
      • 9.2.1.1. COMPANY OVERVIEW
      • 9.2.1.2. PRODUCT LIST
      • 9.2.1.3. STRENGTHS & CHALLENGES
    • 9.2.2. BAYER HEALTHCARE
      • 9.2.2.1. COMPANY OVERVIEW
      • 9.2.2.2. PRODUCT LIST
      • 9.2.2.3. STRENGTHS & CHALLENGES
    • 9.2.3. CARDIOLYSE
      • 9.2.3.1. COMPANY OVERVIEW
      • 9.2.3.2. PRODUCT LIST
      • 9.2.3.3. STRENGTHS & CHALLENGES
    • 9.2.4. CERNER CORPORATION
      • 9.2.4.1. COMPANY OVERVIEW
      • 9.2.4.2. PRODUCT LIST
      • 9.2.4.3. STRENGTHS & CHALLENGES
    • 9.2.5. COGNIZANT
      • 9.2.5.1. COMPANY OVERVIEW
      • 9.2.5.2. PRODUCT LIST
      • 9.2.5.3. STRENGTHS & CHALLENGES
    • 9.2.6. ECLINICAL WORKS INC
      • 9.2.6.1. COMPANY OVERVIEW
      • 9.2.6.2. PRODUCT LIST
      • 9.2.6.3. STRENGTHS & CHALLENGES
    • 9.2.7. EPIC SYSTEMS CORPORATION
      • 9.2.7.1. COMPANY OVERVIEW
      • 9.2.7.2. PRODUCT LIST
      • 9.2.7.3. STRENGTHS & CHALLENGES
    • 9.2.8. INTEL CORPORATION
      • 9.2.8.1. COMPANY OVERVIEW
      • 9.2.8.2. PRODUCT LIST
      • 9.2.8.3. STRENGTHS & CHALLENGES
    • 9.2.9. KOMODO HEALTH
      • 9.2.9.1. COMPANY OVERVIEW
      • 9.2.9.2. PRODUCT LIST
      • 9.2.9.3. STRENGTHS & CHALLENGES
    • 9.2.10. MEDITECH
      • 9.2.10.1. COMPANY OVERVIEW
      • 9.2.10.2. PRODUCT LIST
      • 9.2.10.3. STRENGTHS & CHALLENGES
    • 9.2.11. MICROSOFT CORPORATION
      • 9.2.11.1. COMPANY OVERVIEW
      • 9.2.11.2. PRODUCT LIST
      • 9.2.11.3. STRENGTHS & CHALLENGES
    • 9.2.12. PREDIXION HEALTHCARE (JVION LLC)
      • 9.2.12.1. COMPANY OVERVIEW
      • 9.2.12.2. PRODUCT LIST
      • 9.2.12.3. STRENGTHS & CHALLENGES
    • 9.2.13. SAS INSTITUTE
      • 9.2.13.1. COMPANY OVERVIEW
      • 9.2.13.2. PRODUCT LIST
      • 9.2.13.3. STRENGTHS & CHALLENGES
    • 9.2.14. SIEMENS HEALTHINEERS
      • 9.2.14.1. COMPANY OVERVIEW
      • 9.2.14.2. PRODUCT LIST
      • 9.2.14.3. STRENGTHS & CHALLENGES